중요한 수치까지 담은 화합물 159종.

Body Protection Compound — gut, tendon, and vascular repair. Most-studied healing peptide; popular starter compound.

Long-acting GHRH analog via Drug Affinity Complex. Weekly dosing rationale, sleep and recovery tracking.

Copper peptide — skin, hair, and wound-healing. Measurements, photography, realistic timelines.

Most dangerous compound on the menu — hypoglycemia risk is acute. Medical use only.

Selective growth-hormone secretagogue — clean profile, minimal cortisol/prolactin spike.

An orally active ghrelin-mimetic growth hormone secretagogue (ibutamoren) that raises GH and IGF-1 pulses. It is not a SARM despite often being grouped with them.

A daily pill form of semaglutide, the same GLP-1 receptor agonist as the injectable, approved for chronic weight management and launched in January 2026. Absorption depends on strict fasted dosing.

Oral small-molecule GLP-1 receptor agonist taken as a once-daily pill with no food or water timing restrictions. FDA-approved for chronic weight management in April 2026 under the brand Foundayo.

Triple-agonist (GLP-1 / GIP / glucagon). Strongest weight-loss in trials; titration + safety guidance.

Long-acting GLP-1 agonist (Ozempic / Wegovy). Now also available as an oral 25 mg tablet approved for weight management (launched Jan 2026) — see the Oral Semaglutide entry.

Full-length GHRH analog. Realistic expectations for sleep, recovery, and IGF-1 changes.

Recombinant human growth hormone. Requires serious safety + dose discipline; bloodwork-driven.

Thymosin Beta-4 fragment — soft-tissue and tendon recovery. Long half-life relative to fragment size.

Dual GLP-1 / GIP agonist (Mounjaro / Zepbound). In Dec 2024 Zepbound also became the first drug FDA-approved for obstructive sleep apnea in adults with obesity.

Copper tripeptide focused on hair and scalp. Comparison with GHK-Cu; tracking hair/skin changes.

Non-steroidal aromatase inhibitor (Arimidex). Lowers estrogen on aromatizing androgen cycles.

Modified HGH fragment — fat-loss focus, lipolytic. Failed obesity trials; protocol design implications.

A long-acting dopamine agonist that lowers prolactin, used to manage hyperprolactinemia and related sexual dysfunction. High chronic doses carry a cardiac valve risk.

A once-weekly fixed combination of the amylin analog cagrilintide and semaglutide delivering roughly 22.7% average body-weight loss in trials. It is not yet approved, with regulatory filing expected in late 2026.

A PPAR-delta agonist (GW-501516) usually grouped with SARMs although it is not a true androgen modulator. It is best known for boosting endurance and fat oxidation.

Pulsatile GHRH (Mod GRF 1-29) — mimics natural growth-hormone pulses, daily dosing required.

A long-acting beta-2 agonist used off-label as a thermogenic fat-loss agent. It raises metabolic rate but stresses the cardiovascular system.

Fertility SERM. Stimulates LH/FSH to restore endogenous testosterone and sperm production.

Weekly GLP-1 agonist (Trulicity). Clean titration ladder; tradeoff assessment vs newer compounds.

The trans-isomer of clomiphene, a selective estrogen receptor modulator (SERM) used as a testosterone-replacement alternative. It raises endogenous testosterone while preserving fertility.

Khavinson tetrapeptide. Telomerase research; effects accumulate over cycles, short-protocol courses.

Appetite-forward GH secretagogue. Strong hunger response; useful for bulking-phase tracking.

Master antioxidant — IV vs oral bioavailability is the central tracking question.

Human chorionic gonadotropin. TRT support and fertility protocols; specific metrics for both contexts.

Strongest older GHRP. Faster desensitization than newer compounds; short cycles required.

HGH C-terminal fragment. Fat-loss focus without IGF stimulation; protocol structure with measurable markers.

Extended-half-life IGF-1 analog. Hypoglycemia warning — careful protocol design + measurement required.

Anti-inflammatory tripeptide. Logging framework across gut, skin, and inflammatory endpoints.

A potent oral SARM (LGD-4033) valued for size and strength gains at low milligram doses. It reached early human trials for muscle wasting.

The synthetic form of the active thyroid hormone T3, prescribed for hypothyroidism and used off-label to accelerate fat loss. Exogenous dosing suppresses natural thyroid output.

Daily GLP-1 agonist (Saxenda / Victoza). Daily-injection-class tradeoffs vs weekly compounds.

A once-weekly dual glucagon (GCG) and GLP-1 receptor agonist. It was approved in China in June 2025 for weight management but is not approved in the US or EU.

Tanning peptide. Loading + maintenance protocols, photos, realistic pigment timelines.

Sleep hormone. Most people take 10x too much — precision dosing improves outcomes meaningfully.

Dianabol — classic oral bulker. Fast mass + water gain, heavy estrogenic and hepatic load.

Mitochondrial-encoded peptide. Real biology, modest human data; metabolic and exercise endpoints.

Deca-Durabolin — long-ester nandrolone. Joint-comfort reputation, slow build, slow clear.

NAD+ precursor with extensive supplementation evidence. Comparison with NMN; realistic outcomes.

NAD+ precursor — debated oral bioavailability. Focused on measurable human outcomes vs marketing.

The mildest and most-studied selective androgen receptor modulator, known clinically as enobosarm (MK-2866). It was investigated as a treatment for muscle wasting.

Anavar — a "mild" oral DHT derivative. Liver-strain and lipid impact still real.

Social neuropeptide via intranasal route. Honest framing — literature limits + situational protocols.

Melanocortin agonist — sexual response. On/off effect profile; common attribution errors to avoid.

A strong oral SARM (testolone) marketed for pronounced strength and lean mass gains. It was originally explored for muscle wasting and breast cancer.

An approved mTOR-inhibiting immunosuppressant explored off-label for longevity using intermittent weekly dosing. Interest centers on its effects on cellular aging pathways.

Anxiolytic heptapeptide. Solo framework separating signal from placebo; objective metrics matter.

ACTH fragment for focus / cognition. Solo framework separating effects from caffeine and sleep.

Winstrol — oral DHT derivative known for harsh lipid effects and joint dryness.

Four-ester testosterone blend — staggered release from propionate to decanoate.

SERM (Nolvadex). Blocks estrogen at the breast + restarts the HPG axis in post-cycle protocols.

GHRH analog — visceral-fat reduction. FDA-approved for HIV lipodystrophy. Protocol with measurable markers.

Long-ester testosterone, near-identical to enanthate. Standard US TRT preparation.

Long-ester testosterone — the TRT and bulking backbone. Weekly injection, broad clinical history.

A very long-ester testosterone used for TRT, available as the injectables Nebido and Aveed and the oral Jatenzo. Its long half-life allows dosing every several weeks.

Fast-acting trenbolone — frequent injections, same potency and risk profile as the enanthate.

A potent injectable nandrolone-like androgen (7-alpha-methyl-19-nortestosterone) with strong anabolic activity. It is heavily suppressive and aromatizes to a potent estrogen.

NNMT inhibitor — metabolic research. Limited human data; tracking framework for the available signals.

An early oral SARM (S4) known for a drier, harder look and strength gains. It was never approved and has largely been superseded by newer SARMs.

Tissue-protective peptide developed for small-fiber neuropathy. Pain + inflammation tracking.

Topical "Botox-like" peptide — reduces expression-line depth by limiting muscle contraction signals.

Equipoise (EQ) — very long ester, slow lean gains, raises red-blood-cell count.

Pre-mixed BPC-157 / TB-500 recovery stack — convenience versus dose-flexibility tradeoffs.

Long-acting amylin analog. Now discussed mainly as half of CagriSema (with semaglutide) — REDEFINE data ~22.7% loss, filing expected late 2026.

Calcium-regulating peptide. Bone and calcium-disorder clinical protocols with responsible tracking.

Porcine-brain peptide mixture — neurotrophic research, used clinically for stroke/dementia abroad.

Pre-mixed CJC-1295 No-DAC + Ipamorelin. Pre-mix vs separate-vial tracking implications.

An injectable non-aromatizing anabolic steroid (1-testosterone) known for lean strength gains. It is notorious for severe post-injection pain.

Long-ester Masteron — same DHT-derived compound, weekly dosing instead of EOD.

Short-ester Masteron — DHT-derived, valued for a dry/hard look in lean users.

Delta sleep-inducing peptide. Converts vague sleep impressions into measurable deep-sleep data.

Steroidal (suicidal) aromatase inhibitor (Aromasin). Irreversibly binds aromatase, gentler on lipids.

Original GLP-1 (Byetta / Bydureon) — Gila monster venom-derived. Twice-daily or weekly formulations.

Oral 5-alpha-reductase inhibitors that lower DHT to slow hair loss and treat benign prostatic hyperplasia (BPH). Finasteride is selective while dutasteride blocks more of the enzyme.

A plant flavonoid studied as a senolytic — a compound that clears senescent cells — typically taken in short hit-and-run pulses. Most evidence to date is preclinical.

A potent 17-alpha-alkylated oral androgen prized for raw strength and aggression rather than size. It carries a very high hepatotoxic burden.

Classic ghrelin-mimetic GH secretagogue. Strong GH release; tracks alongside cortisol and prolactin.

Pre-mixed GHK-Cu / BPC-157 / TB-500. Proprietary blend — attribution challenges for outcomes.

GnRH agonist — HPG-axis support during TRT, fertility maintenance. Pulsatile dosing.

Truncated short-acting IGF-1 variant. Site-specific activity; bodybuilding research context.

Classic GHRH + GHRP pairing. Comparison of paired GH-releasing peptides with protocol structure and tracking.

Upstream HPG-axis signal. Reproductive-hormone research; logging focused on HPG endpoints.

Potent non-steroidal aromatase inhibitor (Femara). Easy to over-suppress estrogen — small doses.

A topical collagen-signaling peptide (palmitoyl pentapeptide-4) widely used in anti-aging skincare. It aims to stimulate collagen for firmer, smoother skin.

Muscle-damage-responsive IGF-1 splice variant. Very short half-life, post-workout timing critical.

Slower, cleaner MT cousin — slower onset. FDA-approved for erythropoietic protoporphyria.

An oral DHT derivative that lowers SHBG and supports libido rather than driving large muscle gains. It is often used as an ancillary alongside other compounds.

Prescription longevity drug. Tracking guide accounting for prescription status + GI side effects.

A 17-alpha-alkylated oral anabolic steroid (methyldrostanolone) known for rapid strength and mass gains. It is notably harsh on the liver and blood lipids.

Primobolan — a milder DHT-derived anabolic with a low-side-effect reputation. Still suppressive.

N-acetyl, amidated Selank — more stable, longer-acting variant of the anxiolytic heptapeptide.

N-acetyl, amidated Semax — more stable, longer-acting variant of the ACTH-fragment nootropic.

Direct NAD+ — IV or subcutaneous. Tracking framework weighing cost vs evidence.

Reduced NAD+ form. Oral framework for fatigue, cognition, and Parkinson-disease contexts.

NPP — short-ester nandrolone. Same compound as Deca, faster on and off.

Synthetic nootropic. Oral protocol; task-based cognitive metrics over subjective impressions.

Anadrol — potent oral bulker. Large rapid mass gain with strong hepatic and blood-pressure load.

PEGylated MGF — much longer half-life than native MGF, weekly dosing schedule.

A family of nootropics including piracetam, aniracetam and phenylpiracetam, used for cognition and focus. Potency and stimulation vary widely across the class.

A breast-selective SERM used to treat and prevent gynecomastia and to protect bone density. It antagonizes estrogen in breast tissue while acting as an agonist in bone.

Older clinical bone-density use. Bone-density and calcium-marker tracking framework.

Two popular Russian nootropics. Objective metrics framework for paired nootropic protocols.

Pre-mixed Sermorelin + Ipamorelin (GHRH + GHRP). Practical for daily dosing; tradeoffs vs separates.

A topical peptide (acetyl octapeptide-3) used in cosmetic serums as a needle-free Botox-mimetic. It aims to soften the look of expression lines at the skin surface.

A naturally occurring polyamine, available as a supplement, that induces autophagy — the cell's self-cleaning process. It is being studied for its links to healthy aging.

A REV-ERB agonist (stenabolic) often grouped with SARMs although it acts on circadian metabolism rather than androgen receptors. It has been studied mainly in rodents.

Decision framework for stacking vs cycling BPC-157 and TB-500 separately. Tracking implications for both routes.

Short-ester testosterone — frequent injections, faster clearance, easier to stop.

Approved immune peptide (Zadaxin). Clinical history for hep B/C; protocol + tracking guidance.

A tamoxifen-like SERM used for estrogen control and gynecomastia management, with a generally cleaner lipid profile than tamoxifen. It also helps support endogenous testosterone.

Long-ester trenbolone — extremely potent, high side-effect burden. Not a beginner compound.

GnRH agonist with clinical uses including post-cycle HPG restoration. Off-label restart tracking.

Oral Turinabol — milder, non-estrogenic, steady lean gains. Still 17aa and suppressive.

A gut-derived metabolite, sold as Mitopure, that promotes mitophagy — the recycling of damaged mitochondria. Human trials report gains in muscle endurance.

Branded BPC-157 / TB-500 pre-mix — same compounds, naming convention only. Flexibility loss for convenience.

A synthetic steroidal compound marketed as a SARM that is also claimed to inhibit myostatin. Human data are minimal and it is poorly characterized.

An investigational GLP-1 and amylin receptor agonist being developed in both oral and subcutaneous forms. It entered Phase 3 development in 2026 and is not approved.

Single-chain relaxin analog. Fibrosis and cardiac research; limited human data.

An investigational anti-activin type II receptor monoclonal antibody given by infusion that adds skeletal muscle while reducing fat mass. It is being studied alongside GLP-1 therapies and is not approved.

Preclinical angiotensin-derived nootropic — synaptogenesis research. Essentially no human data.

A mitochondrial uncoupler that forces the body to burn energy as heat, producing dramatic fat loss. It is extremely dangerous, with a narrow margin between an effective dose and a lethal one.

A once-weekly cAMP-biased GLP-1 receptor agonist. Approved in China for chronic weight management and for type 2 diabetes; not approved in the US, UK or EU.

An investigational once-weekly selective amylin receptor agonist, advancing to Phase 3. It is not approved for any use.

Experimental myostatin inhibitors — follistatin-based agents and ACE-031, a soluble activin receptor — aimed at removing the brake on muscle growth. Human use is investigational.

Approved GLP-2 analog (teduglutide) — short bowel syndrome. Gut-focused tracking framework.

Mitochondrial-DNA-encoded peptide. Early-stage neuroprotection / metabolic research.

Energy + fat oxidation. Oral, injectable, and IV protocols with realistic expectations.

Cathelicidin antimicrobial peptide. Limited human data; framework focuses on infection and inflammation markers.

An investigational antibody-peptide conjugate given subcutaneously once a month or less often, in Phase 3. It is not approved for any use.

CNTF-derived speculative research peptide. Minimal human evidence; honest tracking if used experimentally.

Spadin-derived TREK-1 blocker — research-stage antidepressant peptide. Animal data only.

An investigational once-weekly GLP-1 and glucagon receptor dual agonist designed to spare lean mass during weight loss. It is not yet approved.

An investigational once-weekly amylin analog, and the first amylin tested on its own for obesity rather than alongside a GLP-1. It is not approved for any use.

Short Khavinson peptide. Cognitive and stress tracking; realistic expectations for short courses.

Cardiolipin-binding tetrapeptide. Mitochondrial-disease research; clinical-trial markers.

An investigational once-weekly GLP-1 and glucagon receptor dual agonist studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It has shown promising liver-fibrosis and weight data in trials.

Immune peptide. Older-population thymic-function studies; cycle tracking framework.

Full-length parent molecule of TB-500. Broader anti-inflammatory and immune profile than the fragment.

Hypothalamic tripeptide. Thyroid and prolactin axis research; clinical context tracking.

Comparison guide — pick incretin by side-effect tolerance and tracking needs.

Pituitary hormone (AVP / ADH). Water retention + memory research; clinical-use framing.

Khavinson dipeptide. Immune and longevity research; older-population focus.

An investigational GIP and GLP-1 receptor dual agonist in oral and subcutaneous forms, currently in Phase 3 trials. It is not approved for any use.

A synthetic 34-amino-acid analog of parathyroid hormone-related peptide, PTHrP(1-34). Approved in the US for osteoporosis at high risk of fracture.

A synthetic decapeptide GnRH antagonist, used in fertility treatment to prevent a premature LH surge. Label half-life: 20.6 h with repeated daily injections; after a single injection, 5 h to 63 h depending on the dose.

A synthetic decapeptide GnRH antagonist, used in fertility treatment to prevent a premature LH surge. Label half-life: 12.8 h after one injection, 16.2 h with repeated daily injections.

A synthetic decapeptide bradykinin B2 receptor antagonist. Approved in the US for acute attacks of hereditary angioedema (HAE) in adults.

A synthetic nonapeptide GnRH agonist: it first raises LH, FSH and sex hormones, and continuous daily use then lowers them. The injection cited here is approved in the US for advanced prostate cancer.

A GLP-1 receptor agonist, a synthetic analog of human GLP-1. Its current US label is the fixed combination with insulin glargine (Soliqua 100/33) for type 2 diabetes; the half-life here is lixisenatide’s, from that label.

A cyclic octapeptide somatostatin analogue. Approved in the US for acromegaly and for symptoms of carcinoid tumors and VIPomas. Label elimination half-life: 1.7 to 1.9 h.

A prodrug that releases PTH(1-34) over time. Approved in the US for hypoparathyroidism in adults. The half-life here is the label’s apparent half-life of the PTH it releases.

An amylin analog. Approved in the US for people with type 1 or type 2 diabetes who use mealtime insulin and have not reached their glucose targets.

An 8-amino-acid cyclic peptide melanocortin 4 (MC4) receptor agonist. Approved in the US for weight in specific genetic and hypothalamic forms of obesity.

A parathyroid hormone analog, PTH(1-34). Approved in the US for osteoporosis at high risk of fracture, including osteoporosis from long-term glucocorticoids.

A synthetic 15-amino-acid macrocyclic peptide complement inhibitor. Approved in the US for generalized myasthenia gravis in adults who are anti-AChR antibody positive.